Get regular updates to your inbox.
Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an “unacceptably high” risk of mortality, a new study shows. The study, “Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry,” was…
Read more
Life after a pulmonary hypertension (PH) diagnosis is stressful. As a Type A personality, I’ve often defined my worth by my productivity. But since my PH diagnosis, I am now working to prioritize my health. We live in a society that praises productivity. Hustle culture is encouraged across social…
Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also indicate AV-101, which delivers the medication directly to the lungs, reduced its systemic (whole body) exposure. This is…
What is baggage? According to Merriam-Webster, it’s one of three things: suitcases, transportable equipment, or intangible things such as feelings and circumstances that get in the way. What kind of baggage do people living with pulmonary hypertension (PH) often take everywhere they go? The answer: all of it! In…
Switching from Tracleer (bosentan) to Opsumit (macitentan) improved physical abilities with fewer side effects in some adults with pulmonary arterial hypertension (PAH), a study showed. Replacing Tracleer with Opsumit may be a feasible treatment option in PAH patients who did not fully respond to Tracleer alone or…
Columnist Anna Jeter looks back at the pulmonary hypertension treatments and new technology that have emerged in her lifetime.
Visit the Pulmonary Hypertension News forums to connect with others in the PH community.
Get regular updates to your inbox.
